The US FDA cleared Glenmark's fluticasone propionate nasal spray as a generic equivalent of Flonase, a widely used corticosteroid spray for allergic rhinitis. To win such an approval a generic must be both bioequivalent and therapeutically equivalent to the reference listed drug: it must deliver the same active ingredient into the bloodstream at the same rate and extent, and must match the reference product in dosage form, strength, route of administration, quality and intended use. Marc Kikuchi, President and Business Head of North America at Glenmark, said the clearance builds on the company's existing respiratory franchise in the United States. Glenmark had earlier, on 4 March 2026, obtained final US FDA approval through Glenmark Specialty SA for fluticasone propionate inhalation aerosol USP, 44 mcg per actuation, a generic equivalent of GSK's Flovent HFA.

The United States is the largest export market for Indian pharmaceutical companies, and approvals of this kind are how Indian firms convert manufacturing capacity into overseas revenue. India is the world's largest supplier of generic medicines by volume, and each US FDA clearance adds one more product to that pipeline. For Glenmark specifically, a nasal spray is a complex generic rather than a simple tablet, which usually means fewer competitors and better margins than in plain oral generics.